Exogenous estrogens and endometrial cancer

References

• Dorn HF, Cutler SJ: Morbidity From Cancer in the United States. US Department of Health, Education, and Welfare. Part 1, Monograph 29, 1955; Part 2, Monograph 56, 1959. Available from Superintendent of Documents, Washington, DC
   Google Scholar
• Cutler SJ, Young JL Jr: Third National Cancer Survey: Incidence Data. Monograph 41. Bethesda, MD, National Cancer Institute, 1975. Available from Superintendent of Documents, Washington, DC
   Google Scholar
• Cramer DW, Cutler SJ, Christine B: Trends in the incidence of endometrial cancer in the United States. Gynecol Oncol 2:130–143, 1974
   PubMedGoogle Scholar
• Ziel HK, Finkle WD: Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med 293:1167–1170, 4 Dec 1975
   PubMed Web of Science ®Google Scholar
• Smith DC, Prentice R, Thompson DJ, et al: Association of exogenous estrogen and endometrial carcinoma. N Engl J Med 293:1164–1167, 4 Dec 1975
   PubMed Web of Science ®Google Scholar
• Mack TM, Pike MC, Henderson BE, et al: Estrogens and endometrial cancer in a retirement community. N Engl J Med (in press)
   Google Scholar
• Sommers SC: Significance of endometrial hyperplasia and its early diagnosis. In Graber HR, Graber EA (Editors): Gynecological Oncology. Baltimore, The Williams & Wilkins Co, 1970
   Google Scholar
• Shanklin DR: Endometrial cancer: A worsening problem. Consultant 14:94–99, 1974
   Google Scholar
• MacMahon B: Risk factors for endometrial cancer. Gynecol Oncol 2:122–129, 1974
   PubMedGoogle Scholar
• Dunn LJ, Bradbury JT: Endocrine factors in endometrial carcinoma: A preliminary report. Am J Obstet Gynecol 97:465–471, 15 Feb 1967
   PubMed Web of Science ®Google Scholar
• Gordan GS, Eisenberg E, Loken HF, et al: Clinical endocrinology of parathyroid hormone excess. Recent Prog Horm Res 18:297–336, 1972
   Google Scholar
• Boston Collaborative Drug Surveillance Program: Reserpine and breast cancer. Lancet 2:669–671, 21 Sep 1974
   PubMedGoogle Scholar
• Armstrong B, Stevens N, Doll R: Retrospective study of the association between use of rauwolfia derivatives and breast cancer in English women. Lancet 2:672–675, 21 Sep 1974
   PubMed Web of Science ®Google Scholar
• Heinonen OP, Shapiro S, Tuominen L, et al: Reserpine use in relation to breast cancer. Lancet 2:675–677, 21 Sep 1974
   PubMed Web of Science ®Google Scholar
• Rauwolfia derivatives and cancer. (Editorial) Lancet 2:701–702, 21 Sep 1974
   Google Scholar
• O'Fallon WM, Labarthe DR, Kurland LT: Rauwolfia derivatives and breast cancer: A case/control study in Olmsted County, Minnesota. Lancet 2:292–296, 16 Aug 1975
   PubMed Web of Science ®Google Scholar
• Laska EM, Siegel C, Meisner M, et al: Matched-pairs study of reserpine use and breast cancer. Lancet 2:296–300, 16 Aug 1975
   PubMed Web of Science ®Google Scholar
• Mack TM, Henderson BE, Gerkins VR, et al: Reserpine and breast cancer in a retirement community. N Engl J Med 292:1366–1370, 26 Jun 1975
   PubMed Web of Science ®Google Scholar
• Rauwolfia and breast cancer. (Editorial) Lancet 2:312–313, 16 Aug 1975
   Google Scholar
• Gordan GS (Editor): The 1951 Year Book of Endocrinology. Chicago, Year Book Medical Publishers Inc, 1951, p 281
   Google Scholar
• Weir RJ, Briggs E, Mack A, et al: Blood pressure in women taking oral contraceptives. Br Med J 1:533–535, Mar 1974
   PubMed Web of Science ®Google Scholar
• Campbell JH, Cummins SD, Kirk DL, et al: Secondary breast cancer of prostatic origin. JAMA 179:458–460, 10 Feb 1962
   PubMed Web of Science ®Google Scholar
• Campbell JH: Secondary breast cancer of prostatic origin. (Letter) JAMA 180:1143–1144, 30 Jun 1962
   Google Scholar
• Henneman PH, Wallach S: A review of the prolonged use of estrogens and androgens in postmenopausal and senile osteoporosis. Arch Intern Med 100:715–723. Nov 1957
   Google Scholar
• Wallach S, Henneman PH: Prolonged estrogen therapy in postmenopausal women. JAMA 171:1637–1642, 21 Nov 1959
   Web of Science ®Google Scholar
• Gordan GS, Picchi J, Roof BS: Antifracture efficacy of long-term estrogens for osteoporosis. Trans Assoc Am Physicians 86:326–332, 1973
   PubMedGoogle Scholar
• Burch JC, Byrd BF, Vaughn WK: Effects of long-term estrogen administration to women following hysterectomy. Front Hormone Res 3:208–214, 1975
   PubMedGoogle Scholar
• Drill VA: Oral contraceptives: Relations to mammary cancer, benign breast lesions, and cervical cancer. Annu Rev Pharmacol 15:367–385, 1975
   PubMedGoogle Scholar
• Østergaard E: Oral anticonception: Side effects and risks. Acta Obstet Gynecol Scand (suppl 1) 48:57–72. 1969
   PubMedGoogle Scholar
• Fechner RE: Breast cancer during oral contraceptive therapy. Cancer 26:1204–1211, Dec 1970
   PubMed Web of Science ®Google Scholar
• Brezina K, Janisch H, Müller-Tyl E: Das Mammogramm unter Kontrazeptiva. Wien Klin Wochenschr 85:785–790, 1973
   PubMedGoogle Scholar
• Rieche K: Long-term treatment of inbred mice with “anovlar.” Arch Geschwulstforsch 29:158–162, 1967
   PubMedGoogle Scholar
• Rudali G, Coëzy E, Gourdon AC: Action d'un anticonceptionnel de synthèse sur la carcinogénèse mammaire de la souris R. Ill. Rev Franc Etud Clin Biol 12:1010–1014, 1967
   PubMedGoogle Scholar
• Weisburger JH, Weisburger EK, Griswold DP Jr, et al: Reduction of carcinogen-induced breast cancer in rats by an anti-fertility drug. Life Sci 7:259–266, 1 Mar 1968
   PubMed Web of Science ®Google Scholar
• McCormick GM, Moon RC: Effect of increasing doses of estrogen and progesterone on mammary carcinogenesis in the rat. Eur J Cancer 9:483–486, 1973
   PubMed Web of Science ®Google Scholar
• Vessey MP, Doll R, Sutton PM: Oral contraceptives and breast neoplasia: A retrospective study. Br Med J 3:719–724, 1972
   PubMed Web of Science ®Google Scholar
• Yoshimoto Y, Moridera K, Imura H: Restoration of normal pituitary gonadotrophin reserve by administration of luteinizing-releasing hormone in patients with hypogonadotropic hypogonadism. N Engl J Med 292:242–245, 1975
   PubMed Web of Science ®Google Scholar
• Albright F, Bloomberg E, Smith PH: Post-menopausal osteoporosis. Trans Assoc Am Physicians 55:298–305, 1940
   Google Scholar
• Albright F, Smith PH, Richardson AM: Postmenopausal osteoporosis: Its clinical features. JAMA 116:2465–2474, 31 May 1941
   Google Scholar
• Albright F: Osteoporosis. Ann Intern Med 27:861–882, 1947
   PubMed Web of Science ®Google Scholar
• Aitken JM, Hart DM, Anderson JB, et al: Osteoporosis after oophorectomy for non-malignant disease in premenopausal women. Br Med J 2:325–328, 12 May 1973
   PubMedGoogle Scholar
• Aitken JM, Hart DM, Lindsay R: Oestrogen replacement therapy for prevention of osteoporosis after oophorectomy. Br Med J 3:515–518, 1973
   PubMed Web of Science ®Google Scholar
• Dalén N, Lamke B, Wallgren A: Bone-mineral losses in oophorectomized women. J Bone Joint Surg 56A:1235–1238, Sep 1974
   Google Scholar
• Meema S, Bunker ML, Meema HE: Preventive effect of estrogen on postmenopausal bone loss. Arch Intern Med 135:1436–1440, Nov 1975
   PubMedGoogle Scholar
• Urist MR, Mazet R Jr, Bechtol CO: Senile osteoporosis as a disorder influencing treatment and end results of fractures of the hip: With a preliminary report on the use of collapatite. Am Surg 25:883–890, Nov 1959
   PubMedGoogle Scholar
• Bruns P: Die allgemeine Lehre von den Knochenbrüchen. Dtsch Chir 27:1–400, 1882
   Google Scholar
• Alffram PA, Bauer GC: Epidemiology of fractures of the forearm: A biochemical investigation of bone strength. J Bone Joint Surg 44A:105–114, 1962
   Web of Science ®Google Scholar
• Alhava EM, Karjalainen P: Mineral content and density of the forearm bones measured by Am-241 gamma ray attenuation method in 80 patients with osteoporotic hip fractures. Ann Clin Res 5:244–247, 1973
   PubMedGoogle Scholar
• Alhava EM, Puittinen J: Fractures of the upper end of the femur as an index of senile osteoporosis in Finland. Ann Clin Res 5:398–403, 1973
   PubMedGoogle Scholar
• Goldsmith NF, Johnston JO: Bone mineral: Effects of oral contraceptives, pregnancy and lactation. J Bone Joint Surg 57A:657–668, Jul 1975
   Google Scholar
• Hernberg CA: Treatment of postmenopausal osteoporosis with oestrogens and androgens. Acta Endocrinol 34:51–59, May 1960
   PubMedGoogle Scholar